Journal Article Review Epublish 13 citations
PubMed: 37894728 DOI: 10.3390/ijms242015048
Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity.
Int J Mol Sci 24(20)
Authors: Alexandra Moisand, Mathilde Madéry, Thomas Boyer, Charlotte Domblides, Céline Blaye, Nicolas Larmonier
Affiliations
- CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 33076 Bordeaux, France. Cancer Biology Graduate Program, UB Grad 2.0, University of Bordeaux, 33076 Bordeaux, France.
- CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 33076 Bordeaux, France.
- Cancer Biology Graduate Program, UB Grad 2.0, University of Bordeaux, 33076 Bordeaux, France.
- Department of Medical Oncology, University Hospital of Bordeaux, 33000 Bordeaux, France.
Abstract
Breast cancers regroup many heterogeneous diseases unevenly responding to currently available therapies. Approximately 70-80% of breast cancers express hormone (estrogen or progesterone) receptors. Patients with these hormone-dependent breast malignancies benefit from therapies targeting endocrine pathways. Nevertheless, metastatic disease remains a major challenge despite available treatments, and relapses frequently ensue. By improving patient survival and quality of life, cancer immunotherapies have sparked considerable enthusiasm and hope in the last decade but have led to only limited success in breast cancers. In addition, only patients with hormone-independent breast cancers seem to benefit from these immune-based approaches. The present review examines and discusses the current literature related to the role of hormone receptor signaling (specifically, an estrogen receptor) and the impact of its modulation on the sensitivity of breast cancer cells to the effector mechanisms of anti-tumor immune responses and on the capability of breast cancers to escape from protective anti-cancer immunity. Future research prospects related to the possibility of promoting the efficacy of immune-based interventions using hormone therapy agents are considered.
MeSH
Immunity, Estrogens, Hormones, Immunotherapy, Receptors, Estrogen, Therapeutics, Breast Neoplasms
Cited by
- Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives. Pharmaceuticals (Basel), 2025
- Metabolic profiles in laryngeal cancer defined two distinct molecular subtypes with divergent prognoses. Front Immunol, 2025
- A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits. Curr Oncol, 2024
- Comprehensive Analysis of Receptor Status, Histopathological Classifications (B1-B5), and Cumulative Histological Dimensions in Breast Cancer: Predictors of Malignancy and Diagnostic Implications. Cancers (Basel), 2024
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Ther, 2024
- Elucidating Sex-Specific Immune Profiles in a Breast Cancer Model. Int J Mol Sci, 2024
- Estrogen receptors and extracellular matrix: the critical interplay in cancer development and progression. FEBS J, 2025
- Antipsychotic-induced hyperprolactinemia: Toxicologic mechanism and the increased breast cancer risk. Toxicol Rep, 2025
- Comprehensive Analysis of Predictors and Outcomes in Breast Cancer Screening in Romania: Insights from Demographic, Clinical, and Lifestyle Factors. J Clin Med, 2025